CDK2 is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain CDK2 status and malignant solid tumor as inclusion criteria, 4 are phase 2 (3 open) [4].

CDK2 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDK2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK2 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK2 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK2 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK2 is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK2 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].